Ziopharm Oncology Inc (NASDAQ:ZIOP) Short Interest Rose By 0.09%

June 29, 2018 - By Jimmy Cauthen

It was recorded an increase on Ziopharm Oncology Inc (NASDAQ:ZIOP)’s short interest with 0.09%. In June was issued ZIOP’s total 35.65M short interest by FINRA. The up change of 0.09% from 35.62 million shares was reported. Previous ZIOP’s position will need 48 days to recover. It has 751,200 average volume. Ziopharm Oncology Inc float short is 32.78%.

ZIOP hit $3.01 during the last trading session after $0.06 change.ZIOPHARM Oncology, Inc. has volume of 572,478 shares. Since June 29, 2017 ZIOP has declined 31.35% and is downtrending. The stock underperformed the S&P 500 by 43.92%.

ZIOPHARM Oncology, Inc., a biotechnology company, focuses on acquiring, developing, and commercializing a portfolio of cancer therapies that address unmet medical needs through synthetic immuno-oncology.The firm is worth $424.01 million. The company, through its collaboration agreement with Intrexon Corporation, holds certain rights to Intrexon??s synthetic immuno-oncology platform for use in the field of oncology, which includes a clinical stage product candidate, Ad-RTS-IL-12 evaluated for the treatment of metastatic melanoma, unresectable recurrent or metastatic breast cancer, and Grade III malignant glioma .Last it reported negative earnings. The Company’s synthetic immuno-oncology platform employs an inducible gene-delivery system that enables controlled in vivo expression of genes that produce therapeutic proteins to treat cancer.

ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP) Ratings Coverage

A total of 2 analysts rate Ziopharm Oncology (NASDAQ:ZIOP) as follows: 1 “Buy”, 0 “Hold” and 1 “Sell”. Š¢herefore 50% are bullish. (NASDAQ:ZIOP) has 3 ratings reports on Jun 29, 2018 according to StockzIntelligence. On Monday, March 5 the firm earned “Buy” rating by H.C. Wainwright. On Monday, June 18 JP Morgan downgraded the shares of ZIOP in report to “Underweight” rating. The stock rating was maintained by H.C. Wainwright with “Buy” on Monday, May 14.

For more ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP) news announced recently go to: Nasdaq.com, Nasdaq.com, Fool.com, Seekingalpha.com or Nasdaq.com. The titles are as follows: “Mid-Day Market Update: Verastem Shares Climb On Duvelisib Data; ZIOPHARM Oncology Shares Slide” announced on June 18, 2018, “Investor Expectations to Drive Momentum within ZIOPHARM Oncology, MedEquities Realty Trust, Argan, Churchill …” on June 29, 2018, “Better Buy: Ziopharm Oncology, Inc. vs. Celldex Therapeutics” with a publish date: June 29, 2018, “Ziopharm down 12% premarket on likely delay in Phase 1 CAR-T study” and the last “Mid-Afternoon Market Update: Crude Oil Up Over 1%; Gevo Shares Spike Higher” with publication date: June 18, 2018.

ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP) Institutional Investors Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.